Articles
Ideas shaping biotechnology growth—commercial leadership, launch strategy, and rare disease insights from PharmaKonsult.
How to Right-Size a Rare Disease Commercial Organization
More people do not automatically produce a better rare disease launch. Organization design should follow specialist concentration, access burden and patient-support requirements.
Read ArticlePatient Journey Mapping for Rare Disease Commercialization
Prevalence alone does not define opportunity. Mapping how patients enter care, where diagnosis is delayed and where access breaks down creates a realistic commercial model.
Read ArticleCommercial Strategy for Endocrinology Rare Disease Therapies
Endocrinology rare disease commercialization depends on diagnostic recognition, specialist networks and disciplined access—not pharmacology alone.
Read ArticleCommercial Strategy for Neurology Biotechnology Companies
Neurology commercialization succeeds when scientific partnership, Centers of Excellence and patient pathways are built years before launch—not at approval.
Read ArticlePhase II to Launch: A Commercialization Roadmap for Emerging Biotech
An emerging biotech commercialization roadmap should convert market learning into decisions, capabilities and governance before launch pressure peaks.
Read ArticleFive Commercialization Mistakes Emerging Biotechnology Companies Make
Most launch problems are not mysterious. They are the result of delayed commercial thinking, weak market assumptions and organizations built for the wrong market.
Read ArticleWhat Does It Cost to Build a Commercial Organization for an Emerging Biotech?
Commercialization cost is not a sales-force line item. It is the full operating model required for patients to start therapy.
Read ArticleWhy Commercialization Should Influence Clinical Development
Clinical programs create the science. Commercial thinking determines whether that science can become a therapy patients can actually receive.
Read Article